US pharma: A great time to partner with British companies.

I'm spending a couple of weeks in the US, visiting a variety of biotech and pharma companies, talking about how things are going in the industry as well as helping to solve individual company's problems and issues.

Here's a few thoughts about why it is a really good idea at the moment for US based pharma and biotech companies to give serious consideration to working with British based service companies (like PHASTAR).

1. Outside of the US, the UK has the largest experienced pharmaceutical workforce. There has been a lively pharmaceutical business in the UK since 1842 when Thomas Beecham developed his laxative tablets. Over the last couple of centuries, the UK has gained a huge amount of experience in drug development in the UK. At PHASTAR, over 30% of our team have 15 years or more experience in the industry, with an overall average of 10.7 years industry experience.
2. We share a common language and culture. This makes communication really easy.
3. One in five of the largest selling prescription drugs was developed in the UK.
4. The dollar-pound exchange rate changed significantly in 2016, and the pound is currently around 18% lower than the first half of 2016. It seems unlikely that the pound will recover quickly, so UK resources can deliver extremely good value for money.
5. A UK company, with an experienced hub in the US, is perfectly positioned to work with companies all across the US (including the West Coast).

It is my belief, that the combination of the UK's wealth of experience, alongside the current financial benefit of a weaker pound (from a US point of view), make the UK an extremely strong value proposition to US based pharma and biotech companies.

PHASTAR's US office in North Carolina, has a team of expert statisticians and programmers, who can liaise directly with your US-based drug development teams.